Lebertransplantation als Therapie von seltenen Erkrankungen beim Erwachsenen

Zusammenfassung

Neben den Hauptindikationen, die 95 % aller Patienten haben, welche in Deutschland lebertransplantiert werden, gibt es eine Vielzahl von Erkrankungen, die auch im Erwachsenenalter klinisch manifest werden und zur Indikationsstellung führen. Es können dies Stoffwechselerkrankungen, deren Defekt hauptsächlich in der Leber lokalisiert ist, Missbildungen der lebereigenen Zellen, hepatische Gefäßerkrankungen und seltene Tumoren der Leber sein. Nur für einige Erkrankungen gelten „Standard Exceptions“ bei der Listung. Die exakte Diagnostik und der Zeitpunkt der Transplantation sind entscheidend für die Prognose.

Abstract

In addition to the main indications pertaining to 95 % of all patients receiving liver transplantation in Germany, there are numerous other diseases that may become clinically evident in the adult age and may lead to the decision for liver transplantation. These may be metabolic diseases with their main defect located in the liver, malformations of liver cells, hepatic vascular diseases and rare tumours of the liver. Standard exceptions for the listing are in place only for a limited number of diseases. Exact diagnostics and the point in time for transplantation are crucial for the prognosis.

Schlüsselwörter

Lebertransplantation - seltene Indikation - Allokation

Key words

liver transplantation - rare indications - allocation

• Literatur

• 1 Bundesärztekammer. Richtlinien für die Wartelistenführung und die Organvermittlung gem. § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG. Im Internet: http://www.bundesaerztekammer.de/page.asp?his=7.45.8858.8870 Stand:12. März 2012
• 2 van Keimpema L, Nevens F, Adam R. et al. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int 2011; 24: 1239-1245
• 3 Chandok N, Uhanova J, Marotta P. Clinical outcomes of liver transplantation for polycystic liver disease: a single center experience. Ann Hepatol 2010; 9: 278-281
• 4 Taner B, Willingham DL, Hewitt WR. et al. Polycystic liver disease and liver transplantation: single-institution experience. Transplant Proc 2009; 41: 3769-3771
• 5 Krohn PS, Hillingso JG, Kirkegaard P. Liver transplantation in polycystic liver disease: a relevant treatment modality for adults?. Scand J Gastroenterol 2008; 43: 89-94
• 6 Harring TR, Nguyen NTT, Liu H. et al. Caroli disease patients have excellent survival after liver transplant. J Surg Res 2012; 177: 365-372
• 7 Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl. 01) S26-S35
• 8 Davit-Spraul A, Gonzales E, Baussan C. et al. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009; 4: 1
• 9 Hori T, Egawa H, Takada Y. et al. Progressive familial intrahepatic cholestasis: a single-center experience of living-donor liver transplantation during two decades in Japan. Clin Transplant 2011; 25: 776-785
• 10 Hori T, Egawa H, Miyagawa-Hayashino A. et al. Living-donor liver transplantation for progressive familial intrahepatic cholestasis. World J Surg 2011; 35: 393-402
• 11 Alagille D, Odievre M, Gautier M. et al. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 1975; 86: 63-71
• 12 Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2012; 20: 251-257
• 13 Shneider BL. Liver transplantation for Alagille syndrome: the jagged edge. Liver Transpl 2012; 18: 878-880
• 14 Catana AM, Medici V. Liver transplantation for Wilson disease. World J Hepatol 2012; 4: 5-10
• 15 Arnon R, Kerkar N, Davis MK. et al. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant 2010; 14: 796-805
• 16 Nazer H, Ede RJ, Mowat AP. et al. Wilsonʼs disease: clinical presentation and use of prognostic index. Gut 1986; 27: 1377-1381
• 17 Dhawan A, Taylor RM, Cheeseman P. et al. Wilsonʼs disease in children: 37-year experience and revised Kingʼs score for liver transplantation. Liver Transpl 2005; 11: 441-448
• 18 Cheng F, Li SQ, Zhang F. et al. Outcomes of living-related liver transplantation for Wilsonʼs disease: a Single-center experience in China. Transplantation 2009; 87: 751-757
• 19 Park YK, Kim BW, Wang HJ. et al. Auxiliary partial orthotopic living donor liver transplantation in a patient with Wilsonʼs disease: a case report. Transplant Proc 2008; 40: 3808-3809
• 20 Dar FS, Faraj W, Zaman MB. et al. Outcome of liver transplantation in hereditary hemochromatosis. Transpl Int 2009; 22: 717-724
• 21 Raichlin E, Daly RC, Rosen CB. et al. Combined heart and liver transplantation: a single-center experience. Transplantation 2009; 88: 219-225
• 22 Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant 2010; 15: 269-276
• 23 Sperl J, Prochazkova J, Martasek P. et al. N-acetyl cysteine averted liver transplantation in a patient with liver failure caused by erythropoietic protoporphyria. Liver Transpl 2009; 15: 352-354
• 24 Reddy SK, Austin SL, Spencer-Manzon M. et al. Liver transplantation for glycogen storage disease type Ia. J Hepatol 2009; 51: 483-490
• 25 Chryssostalis A, Hubert D, Coste J. et al. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol 2011; 55: 1377-1382
• 26 Jamieson NV, Jamieson KA. Primary hyperoxaluria type 1: gene therapy by liver transplantation. Transplantation 2009; 87: 1273-1274
• 27 Cochat P, Hulton SA, Acquaviva C. et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012; 27: 1729-1736
• 28 Popescu I, Dima SO. Domino liver transplantation: how far can we push the paradigm?. Liver Transpl 2012; 18: 22-28
• 29 Saner FH, Treckmann J, Pratschke J. et al. Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1. Transplantation 2010; 90: 782-785
• 30 Jamieson NV. A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984–2004. Am J Nephrol 2005; 25: 282-289
• 31 Malde DJ, Pararajasingam R, Tavakoli A. et al. Transplantation in adults with primary hyperoxaluria: single unit experience and treatment algorithm. Ann Transplant 2011; 16: 111-117
• 32 Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation?. J Hepatol 2007; 47: 460-466
• 33 Foss A, Adam R, Dueland S. Liver transplantation for colorectal liver metastases: revisiting the concept. Transpl Int 2010; 23: 679-685
• 34 Chan G, Kocha W, Reid R. et al. Liver transplantation for symptomatic liver metastases of neuroendocrine tumours. Curr Oncol 2012; 19: 217-221
• 35 Gedaly R, Daily MF, Davenport D. et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011; 146: 953-958
• 36 Bioulac-Sage P, Laumonier H, Laurent C. et al. Benign and Malignant Vascular Tumors of the Liver in Adults. Semin Liver Dis 2008; 28: 302-314
• 37 Mehrabi A, Kashfi A, Fonouni H. et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107: 2108-2121
• 38 Lerut JP, Weber M, Orlando G. et al. Vascular and rare liver tumors: a good indication for liver transplantation?. J Hepatol 2007; 47: 466-475
• 39 Lerut JP, Orlando G, Adam R. et al. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg 2007; 246: 949-957 discussion 957
• 40 Grotz TE, Nagorney D, Donohue J. et al. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?. HPB 2010; 12: 546-553
• 41 Orlando G, Adam R, Mirza D. et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation–the European Liver Transplant Registry experience. Transplantation 2013; 95: 872-877
• 42 Maluf D, Cotterell A, Clark B. et al. Hepatic angiosarcoma and liver transplantation: case report and literature review. Transplant Proc 2005; 37: 2195-2199
• 43 Zheng MH, Zhang L, Gu DN. et al. Hepatoblastoma in adult: review of the literature. J Clin Med Res 2009; 1: 13-16
• 44 Rougemont AL, McLin VA, Toso C. et al. Adult hepatoblastoma: learning from children. J Hepatol 2012; 56: 1392-1403
• 45 Ishak KG, Goodman ZD, Stocker JT. Atlas of Tumor Pathology. Tumors of the liver and intrahepatic bile ducts. Hepatoblastoma. 2nd ed.. Washington, DC: American Registry of Pathology; 2001
• 46 Di Sandro S, Slim AO, Lauterio A. et al. Liver adenomatosis: a rare indication for living donor liver transplantation. Transplant Proc 2009; 41: 1375-1377
• 47 Hajdu CH, Murakami T, Diflo T. et al. Intrahepatic portal cavernoma as an indication for liver transplantation. Liver Transpl 2007; 13: 1312-1316
• 48 Shamseddine A, Faraj W, Mukherji D. et al. Unusually young age distribution of primary hepatic leiomyosarcoma: case series and review of the adult literature. World J Surg Oncol 2010; 8: 56
• 49 Darwish Murad S, Plessier A, Hernandez-Guerra M. et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175
• 50 Mancuso A. Budd-Chiari syndrome management: Lights and shadows. World J Hepatol 2011; 3: 262-264
• 51 Campos-Varela I, Castells L, Dopazo C. et al. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl 2012; 18: 201-205
• 52 Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol 2012; 56 (Suppl. 01) S25-S38
• 53 Shovlin CL, Guttmacher AE, Buscarini E. et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67
• 54 Dupuis-Girod S, Chesnais AL, Ginon I. et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl 2010; 16: 340-347
• 55 Lerut J, Orlando G, Adam R. et al. Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry. Ann Surg 2006; 244: 854-862 discussion 862–864
• 56 Moore EE, Cogbill TH, Jurkovich GJ. et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995; 38: 323-324
• 57 Heuer M, Kaiser GM, Lendemans S. et al. Transplantation after blunt trauma to the liver: a valuable option or just a “waste of organs”?. Eur J Med Res 2010; 15: 169-173
• 58 Voigtlander T, Negm AA, Schneider AS. et al. Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome. Endoscopy 2012; 44: 1055-1058
• 59 Vanatta JM, Modanlou KA, Dean AG. et al. Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. Liver Transpl 2011; 17: 1027-1034
• 60 Schoenlank F. Ein Fall von Peliosis hepatis. Virchows Arch [Path Anat] 1916; 222: 358
• 61 Bexten T, Burck I, Bechstein WO. et al. [Hepatic peliosis – a rare liver tumor and challenge for diagnostic investigation plus therapy]. Dtsch Med Wochenschr 2012; 137: 1505-1509